Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day

Rhea-AI Summary

Foghorn Therapeutics (Nasdaq: FHTX) will participate in the 2022 Guggenheim Targeted Protein Degradation Day on March 16, 2022, at 9:30 a.m. ET. The event will be held virtually, featuring a fireside chat that highlights Foghorn's innovative work in oncology through its Gene Traffic Control platform. The webcast will be accessible on their website for 90 days following the event. Foghorn focuses on discovering medicines that address genetically determined dependencies in the chromatin regulatory system, with multiple oncology product candidates currently in clinical studies.

CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Foghorn^® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Foghorn will participate at the 2022 Guggenheim Targeted Protein Degradation Day which is being held virtually on March 16^th, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control^® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Fireside chat date and time: Wednesday, March 16^th, 2022, at 9:30 a.m. ET

Please find a link to the fireside chat here.

The webcast can also be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will remain available for 90 days.

About Foghorn Therapeutics
Foghorn^® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control^® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology with two currently being investigated in clinical studies.

Contact:

Ben Strain, Foghorn Therapeutics (Media and Investors)
bstrain@foghorntx.com

Gregory Kelley, Ogilvy (Media)
gregory.kelley@ogilvy.com

Hans Vitzthum, LifeSci Advisors (Investors)
hans@lifesciadvisors.com

FAQ

When is Foghorn Therapeutics participating in the Guggenheim Targeted Protein Degradation Day?

Foghorn Therapeutics will participate on March 16, 2022, at 9:30 a.m. ET.

How can I access the Foghorn Therapeutics fireside chat?

The fireside chat can be accessed via a link provided in the press release or on Foghorn's website under 'Events & Presentations.'

What is Foghorn Therapeutics' Gene Traffic Control platform?

The Gene Traffic Control platform is Foghorn's proprietary method for discovering and developing a novel class of medicines targeting chromatin regulatory systems.

What focus areas does Foghorn Therapeutics specialize in?

Foghorn Therapeutics specializes in oncology, developing multiple product candidates currently under clinical study.

How long will the webcast from Foghorn Therapeutics be available?

The webcast will remain available for 90 days following the event.